Serum level of soluble triggering receptor expressed on myeloid cells-1 as a biomarker of disease activity in relapsing polychondritis

REFERENCES

• Jaksch-Wartenhorst R. Polychondropathia. Wien Arch Inn Med. 1923;6:100.
   Google Scholar
• Pearson CM, Kline HM, Newcomer VD. Relapsing polychon-dritis. N Engl J Med. 1960;263:51–8.
   PubMed Web of Science ®Google Scholar
• Lahmer T, Treiber M, von Werder A, Foerger F, Knopf A, Heemann U, et al. Relapsing polychondritis: an autoimmune disease with many faces. Autoimmun Rev. 2010;9:540–6.
   PubMed Web of Science ®Google Scholar
• Kemta Lekpa F, Kraus VB, Chevalier X. Biologics in relapsing polychondritis: a literature review. Semin Arthritis Rheum. 2012;41:712–9.
   PubMed Web of Science ®Google Scholar
• Rapini RP, Warner NB. Relapsing polychondritis. Clin Dermatol. 2006;24:482–5.
   PubMed Web of Science ®Google Scholar
• Foidart JM, Abe S, Martin GR, Zizic TM, Barnett EV, Lawley TJ, et al. Antibodies to type II collagen in relapsing polychon-dritis. N Engl J Med. 1978;299:1203–7.
   PubMed Web of Science ®Google Scholar
• Kempta Lekpa F, Piette JC, Bastuji-Garin S, Kraus VB, Stabler TV, Poole AR, et al. Serum cartilage oligomeric matrix protein (COMP) level is a marker of disease activity in relapsing poly-chondritis. Clin Exp Rheumatol. 2010;28:553–5.
   Google Scholar
• Michet CJ. Diagnostic evaluation of relapsing polychondritis. http://www.uptodate.com/contents/diagnostic-evaluation-of-relapsing-polychondritis.
   Google Scholar
• Terato K, Shimozuru Y, Katayama K, Takemitsu Y, Yamashita I, Miyatsu M, et al. Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthr Rheum. 1990;33:1493–500.
   PubMed Web of Science ®Google Scholar
• Kent PD, Michet CJ Jr, Luthra HS. Relapsing polychondritis. Curr Opin Rheumatol. 2004;16:56–61.
   PubMedGoogle Scholar
• Gomez-Pina V, Soares-Schanoski A, Rodriguez-Rojas A, Del Fresno C, Garcia F, Vallejo-Cremades MT, et al. Metallopro-teinases shed TREM-1 ectodomain from lipopolysaccharide-sti-mulated human monocytes. J Immunol. 2007;179:4065–73.
   PubMed Web of Science ®Google Scholar
• Gibot S, Cravoisy A. Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection. Clin Med Res. 2004;2:181–7.
   PubMedGoogle Scholar
• McAdam LP, O'Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore). 1976;55:193–215.
   PubMed Web of Science ®Google Scholar
• Damiani JM, Levine HL. Relapsing polychondritis-report of ten cases. Laryngoscope. 1979;89:929–46.
   PubMed Web of Science ®Google Scholar
• Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000;164: 4991–5.
   Google Scholar
• Chen LC, Laskin JD, Gordon MK, Laskin DL. Regulation of TREM expression in hepatic macrophages and endothelial cells during acute endotoxemia. Exp Mol Pathol. 2008;84:145–55.
   PubMed Web of Science ®Google Scholar
• Gibot S, Kolopp-Sarda MN, Bene MC, Cravoisy A, Levy B, Faure GC, et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with sus-pected sepsis. Ann Intern Med. 2004;141:9–15.
   PubMed Web of Science ®Google Scholar
• Gibot S, Cravoisy A, Kolopp-Sarda MN, Bene MC, Faure G, Bo-llaert PE, et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med. 2005;33: 792–6.
   Google Scholar
• Routsi C, Giamarellos-Bourboulis EJ, Antonopoulou A, Kollias S, Siasiakou S, Koronaios A, et al. Does soluble triggering receptor expressed on myeloid cells-1 play any role in the path-ogenesis of septic shock? Clin Exp Immunol. 2005;142:62–7.
   Google Scholar
• Tzivras M, Koussoulas V, Giamarellos-Bourboulis RI, Tzivras D, Tsaganos T, Koutoukas P, et al. Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel dis-ease. World J Gastroenterol. 2006;12:3416–9.
   Google Scholar
• Kuai J, Gregory B, Hill A, Pittman DD, Feldman JL, Brown T, et al. TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford). 2009;48:1352–8.
   PubMed Web of Science ®Google Scholar
• Daikeler T, Regenass S, Tyndall A, Gencay MM, Roth M, Christ-Crain M, et al. Increased serum levels of soluble triggering receptor expressed on myeloid cells-1 in antineutrophil cytoplasmic anti-body-associated vascufitis. Ann Rheum Dis. 2008;67: 723–4.
   Google Scholar
• Michet CJ. Vasculitis and relapsing polychondritis. Rheum Dis Clin North Am. 1990;16:441–4.
   PubMed Web of Science ®Google Scholar
• Zeuner M, Straub RH, Rauh G, Albert ED, Scholmerich J, Lang B. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol. 1997;24:96–101.
   PubMed Web of Science ®Google Scholar
• Bleharski JR, Kiessler V, Buonsanti C, Siefing PA, Stenger S, Col-onna M, et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J Immunol. 2003;170: 3812–8.
   Google Scholar
• Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 2001;410:1103–7.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Akahoshi T, Aoki N, Toyomoto M, Miyasaka N, Kohsaka H. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoim-mune arthritis. Arthr Rheum. 2009;60:1615–23.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a pre-dictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthr Rheum. 2000;43:852–8.
   PubMed Web of Science ®Google Scholar